ABOS 250117 2.50C (ABOS250117C2500) Stock Options, News & Quotes

0.09
+0.04+80.00%

15min DelayClose Dec 24 13:00 ET

0.09High0.09Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Oct 31 07:20

NEWS

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease
Acumen Pharmaceuticals presented data on using pTau217 assay as an efficient screening tool for their Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer's disease. The assay, with a threshold of ≥0.15 pg/mL, effectively identifie...

Stock_Drift

Oct 23 15:45

After Hours Ticks. 4:44pm

$Rimini Street (RMNI.US)$ $Acumen Pharmaceuticals (ABOS.US)$ $Molina Healthcare (MOH.US)$ $BioVie (BIVI.US)$ $Allakos (ALLK.US)$ $CNS Pharmaceuticals (CNSP.US)$ $GraniteShares 2x Long TSLA Daily ETF (TSLR.US)$ $Direxion Daily TSLA Bull 2X Shares (TSLL.US)$ $T-Rex 2x Long Tesla Daily Target ETF (TSLT.US)$ $Twin Vee PowerCats (VEEE.US)$ $EpicQuest Education (EEIQ.US)$ $Mobile-health Network Solutions (MNDR.US)$
📊⚡️📊

Jaguar8

Jul 28 07:08

NEWS

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference 2024.
The research focuses on patient experiences, biomarker data, and a new ultra-sensitive assay for measuring s...

Jaguar8

Jul 11 07:00

NEWS

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and online ...

Jaguar8

Apr 16 07:04

$Acumen Pharmaceuticals (ABOS.US)$
NEWS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Sabirnetug demonstrated a favorable safety profile with low incidence of ARIA-E in early AD participants.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma bio...